What this Trial Is About

Researchers are continuing to follow participants who were previously involved in the INSIGHT study to better understand the development of preclinical Alzheimer's disease. This regional, single-center, prospective observational study will track subjects aged 70 to 95 years for an additional 5 to 6 years. The main focus is on identifying when participants progress to symptomatic Alzheimer's disease, particularly those at risk due to positive amyloid deposits detected by florbetapir PET imaging. The study plans to include about 240 participants from the original 318, with a lighter follow-up schedule of annual visits instead of every six months. During the study, participants will undergo several evaluations including cognitive and oculomotor tests, blood sampling, lumbar puncture, MRI scans at baseline and at months 12, 36, and 60, as well as PET scans with 18F-Florbetapir to detect amyloid and 18F-fluorodeoxyglucose for brain metabolism. An EEG will be performed only if a participant shows significant cognitive decline or converts to symptomatic Alzheimer's disease. These procedures aim to monitor the natural course of the disease and related brain changes. Participants will be involved in yearly assessments over a five-year period to track changes in cognition and brain function, including neuroimaging and biological sampling. Researchers will evaluate the conversion to symptomatic Alzheimer's disease as the primary outcome. Safety monitoring and data collection will continue throughout the study duration to understand disease progression better and to ensure participant well-being.

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study